SCHEMBL25877625

SCHEMBL25877625

Cc1c(C=O)cc(OCc2ccccc2)c(OCc2ccccc2)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.50
MAPT P10636 4/20 0.50
TDP1 Q9NUW8 3/20 0.50
CCNB2 O95067 1/20 0.50
CDK1 P06493 1/20 0.50
CDK4 P11802 1/20 0.50
CCNB1 P14635 1/20 0.50
CCND1 P24385 1/20 0.50
CCNB3 Q8WWL7 1/20 0.50
MAPK1 P28482 1/20 0.50
PTPN1 P18031 1/20 0.47
ERN1 O75460 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25877626 0.87 MAPT (0.48) L3MBTL1MAPTTDP1CCNB2CDK1
SCHEMBL24140484 0.87 ERN1 (0.49) L3MBTL1MAPTTDP1CCNB2CDK1
SCHEMBL16018687 0.84 MAPT (0.51) L3MBTL1MAPTTDP1CCNB2CDK1
SCHEMBL17523247 0.84 MAPT (0.51) L3MBTL1MAPTTDP1CCNB2CDK1
SCHEMBL15668933 0.83 MAPT (0.59) L3MBTL1MAPTTDP1CCNB2CDK1
SCHEMBL25877366 0.83 ERN1 (0.50) L3MBTL1MAPTTDP1MAPK1PTPN1
SCHEMBL24140500 0.83 ERN1 (0.50) L3MBTL1MAPTTDP1MAPK1ERN1
SCHEMBL25877949 0.81 PTPN1 (0.45) L3MBTL1MAPTTDP1CCNB2CDK1
SCHEMBL25817126 0.81 PTPN1 (0.45) L3MBTL1MAPTTDP1CCNB2CDK1
SCHEMBL25877526 0.81 PTPN1 (0.48) L3MBTL1MAPTTDP1CCNB2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B L3MBTL1 2452/4885MAPT 3694/4885TDP1 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.